Recent Upgrades for Quest Diagnostics
Analysts have expressed renewed optimism for Quest Diagnostics (NYSE: DGX) following a recent upgrade by CFRA analyst Paige Meyer, who moved the rating from Hold to Buy. This decision was accompanied by a revised price target of $178 per share, up from $155. The adjustment highlights confidence in Quest's growth trajectory in the healthcare diagnostics market.
Utilization Trends and Financial Performance
The positive revision is largely attributed to increased utilization trends that are expected to bolster sales growth. The new price target is calculated at 18.4 times the firm's earnings per share (EPS) estimate for 2025, which indicates a valuation premium compared to Quest's historical averages.
Recently released third-quarter earnings showed Quest Diagnostics earning $2.30 per share, which surpassed analyst expectations by $0.04. Additionally, sales reached $2.5 billion, reflecting a 3% increase over consensus estimates, supported by organic growth of 4.2%. This growth was driven by higher volumes and increased revenue from each requisition.
EPS Growth Projections
In light of these developments, Meyer has adjusted EPS forecasts upward, with the 2024 forecast now at $8.89, a $0.03 increase, and the 2025 forecast rising by $0.18 to $9.67. Furthermore, the company has raised its 2024 adjusted EPS guidance by $0.05, reaching a midpoint estimate of $8.90.
The upward revisions are influenced by expectations surrounding the acquisition of LifeLabs, though these gains are slightly tempered by anticipated financial impacts from Hurricane Milton, projected to knock $0.08 off per share.
Business Growth through Acquisitions
Over the course of 2024, Quest Diagnostics completed eight key acquisitions, which Meyer predicts will aid the company in exceeding its revenue growth target of 1% to 2% stemming from acquisitions for the year 2025. However, Meyer anticipates a return to this growth range in 2026 as the benefits of these acquisitions materialize.
The strategic acquisitions underline Quest's positioning within the diagnostics field and highlight its commitment to expansion and innovation within the industry. The market reaction has been positive, reflecting a general sentiment of confidence among investors.
Impressive Third-Quarter Results
In its third-quarter report, Quest Diagnostics significantly topped expectations, posting adjusted EPS of $2.30 which exceeded the consensus estimate of $2.26. Furthermore, revenue reflected an impressive year-over-year growth of 8.5%, culminating in $2.49 billion and outpacing analyst forecasts of $2.43 billion.
The positive performance can be attributed to several factors: successful customer acquisitions, enhanced collaboration with both healthcare providers and hospitals, and impactful recent acquisitions, notably LifeLabs. In response to this performance, Quest has revised its full-year revenue guidance upward to a range of $9.80 billion to $9.85 billion, an improvement from their prior estimate of $9.50 billion to $9.58 billion.
Future Outlook and Dividend Strategy
Despite this strategic upward revision, Quest Diagnostics has maintained its adjusted EPS guidance of $8.85 to $8.95. The company links its improved revenue outlook to recent acquisitions and expresses strong confidence in its capacity to foster rapid revenue and earnings growth in the coming year.
According to recent insights, Quest Diagnostics has a market capitalization of $17.56 billion, solidifying its strong foothold in the healthcare diagnostics industry. Demonstrating commitment to its shareholders, the company has consistently delivered dividend payments for 21 consecutive years, offering a current yield of 2.04% and a growth rate of 5.63% over the last year.
Investing Insights
Quest's price-to-earnings (P/E) ratio stands at 21.04, while the adjusted P/E ratio is at 19.71, suggesting that investors are ready to trade at a premium for the company's earnings potential. This sentiment aligns with the upgraded outlook provided by CFRA.
Furthermore, revenue figures for the previous twelve months tally at $9.346 billion, growing quarterly by 2.52% in the second quarter of 2024. This trend reinforces the predictions of continued sales growth and increased utilization moving forward.
Frequently Asked Questions
What was the recent change in Quest Diagnostics’ rating?
CFRA analyst Paige Meyer upgraded Quest Diagnostics from Hold to Buy, raising the price target to $178.
What contributed to the upgrade in Quest Diagnostics' price target?
The upgrade was based on increased utilization trends and strong sales performance exceeding expectations.
How much did Quest Diagnostics earn in its latest quarter?
Quest Diagnostics reported earnings of $2.30 per share for the third quarter, outperforming consensus estimates.
What is Quest Diagnostics' current revenue guidance?
The company raised its full-year revenue guidance to between $9.80 billion and $9.85 billion.
How has Quest Diagnostics performed in terms of dividend payments?
Quest has maintained dividend payments for 21 consecutive years, reflecting its commitment to returning value to shareholders.
